SNDX

NEUTRAL

$24.23 Live

Syndax Pharmaceuticals, Inc. · NASDAQ

Target $39.0 (+61.0%)

$8.58 52W Range $25.59

SNDX Syndax Pharmaceuticals, Inc. - Fundamental Analysis

NEUTRAL

Console Chart News

SNDX Stock | Fundamental Analysis & Investment Insights

NASDAQ • Healthcare • Biotechnology

Current Price Live

$24.23

Analyst Target

$39.0

+61.0% Upside

52W High

$25.59

52W Low

$8.58

Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 20, 2026

Market cap

$2.14B

P/E

N/A

ROE

-161.8%

Profit margin

-165.6%

Debt/Equity

5.34

Dividend yield

N/A

AI Analysis

AI-powered fundamental assessment

Confidence

85%

SNDX presents a classic high-risk, high-reward biotechnology profile, characterized by a weak Piotroski F-Score of 2/9 indicating poor fundamental health. While the company exhibits explosive revenue growth (794.9% YoY) and strong analyst support with a $39 target, its financial structure is fragile with a high Debt/Equity ratio of 5.34 and deeply negative profit margins. The divergence between the 'Strong Buy' analyst consensus and the bearish insider selling/technical trend suggests a speculative environment where growth expectations are pricing in future success despite current operational losses.

Key Strengths

Explosive YoY revenue growth of 794.90%

Strong short-term liquidity with a Current Ratio of 4.40

Strong analyst consensus (Strong Buy) with a significant upside target of $39.00

Impressive 1-year price appreciation of 110%

Positive YoY EPS growth of 29.1% despite remaining unprofitable

Key Risks

Very weak Piotroski F-Score (2/9) signaling deteriorating financial health

High leverage with a Debt/Equity ratio of 5.34

Severe negative profitability (Profit Margin: -165.60%, Gross Margin: -54.19%)

Extreme valuation premiums (Price/Book: 32.79, Price/Sales: 12.40)

Bearish insider activity with CEO and CFO selling shares

AI Fair Value Estimate

Based on comprehensive analysis

$31.5

+30.0% above current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Weak

Value

Future

Past

Health

Dividend

AI Verdict

Speculative Growth

Key drivers: Hyper-growth in revenue, Poor fundamental health scores, High valuation multiples, Strong analyst optimism

Confidence

90%

Value

20/100

Trades at a massive premium to book value; valuation is based entirely on future growth projections.

Positives

No standout positives identified.

Watchpoints

P/B of 32.79 is extremely high
P/S of 12.40 suggests expensive entry
No Graham Number available due to lack of earnings

Future

85/100

Growth metrics are the primary driver of the current stock price.

Positives

794.9% Revenue growth
Strong analyst target price ($39)
Positive EPS growth trend

Watchpoints

Dependence on clinical/regulatory success

Past

50/100

Strong price momentum over the last year, but historical profitability is non-existent.

Positives

110% 1-year return
Consistent earnings beats in several previous quarters

Watchpoints

Long history of negative earnings

Health

15/100

Fundamental health is weak; the company is burning cash to fuel growth.

Positives

Current Ratio of 4.40 provides a liquidity cushion

Watchpoints

Piotroski F-Score of 2/9 is critically low
Debt/Equity of 5.34 is excessive
Negative gross margins

Dividend

0/100

Typical for biotech; all capital is reinvested or used for operations.

Positives

No standout positives identified.

Watchpoints

No dividend paid
0/100 dividend strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$24.23

Analyst Target

$39.0

Upside/Downside

+61.0%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for SNDX and closest competitors.

Updated 2026-04-17

Company	5Y	3Y	1Y	6M	1M	1W
SNDX Syndax Pharmaceuticals, Inc. Primary	+25.0%	+18.8%	+110.0%	+69.4%	+2.5%	-0.9%
AHG Akso Health Group Peer	+24.4%	+547.7%	+88.2%	+30.8%	+77.3%	+85.2%
ACHC Acadia Healthcare Company, Inc. Peer	-61.4%	-66.0%	-16.5%	+8.2%	+51.5%	-8.2%
NEOG Neogen Corporation Peer	-79.3%	-40.3%	+78.0%	+62.6%	+5.5%	-3.7%
PAHC Phibro Animal Health Corporation Peer	+144.3%	+265.7%	+224.4%	+40.4%	+2.6%	-8.8%

SND

Syndax Pharmaceuticals, Inc.

Primary

+25.0%

+18.8%

+110.0%

+69.4%

+2.5%

-0.9%

AHG

Akso Health Group

Peer

+24.4%

+547.7%

+88.2%

+30.8%

+77.3%

+85.2%

ACH

Acadia Healthcare Company, Inc.

Peer

-61.4%

-66.0%

-16.5%

+8.2%

+51.5%

-8.2%

NEO

Neogen Corporation

Peer

-79.3%

-40.3%

+78.0%

+62.6%

+5.5%

-3.7%

PAH

Phibro Animal Health Corporation

Peer

+144.3%

+265.7%

+224.4%

+40.4%

+2.6%

-8.8%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

N/A

-44.96

N/A

32.79

12.4

12.0

-7.57

$2.14B

Profitability

Profit margins and return metrics

Profit Margin -165.6%

Operating Margin -91.59%

Gross Margin -54.19%

ROE -161.82%

ROA -27.25%

Growth

Revenue and earnings growth rates

Revenue Growth +794.9%

Earnings Growth N/A

Q/Q Revenue Growth +794.9%

Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

5.34

High debt

Current Ratio

4.4

Strong

Quick Ratio

4.03

Excellent

Cash/Share

$4.69

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue

$0.1B

Gross Margin

96.1%

Op. Margin

-91.0%

Net Margin

-99.0%

Total Assets

$0.5B

Liabilities

$0.5B

Equity

$0.1B

Debt/Equity

7.20x

Operating CF

$-0.1B

CapEx

$-0.0B

Free Cash Flow

$-0.1B

FCF Yield

100%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-04

$N/A

2026-02-26

$-0.78

-34.9% surprise

2025-11-03

$-0.7

+1.5% surprise

2025-08-04

$-0.83

+17.5% surprise

Healthcare Sector Comparison

Comparing SNDX against 470 companies in the Healthcare sector (26 bullish, 143 neutral, 301 bearish)

Return on Equity (ROE)

-161.82%

This Stock

-97.91%

Sector Avg

+65.3% (Excellent)

Profit Margin

-165.6%

This Stock

-16.16%

Sector Avg

+924.7% (Superior)

Debt to Equity

5.34

This Stock

3.0

Sector Avg

+78.2% (Higher)

Revenue Growth

794.9%

This Stock

142.9%

Sector Avg

+456.3% (Fast Growth)

Current Ratio

4.4

This Stock

4.65

Sector Avg

-5.5% (Weaker)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
SNDX Syndax Pharmaceuticals, Inc.	NEUTRAL	$2.14B	-	-161.8%	-165.6%	$24.23
AHG Akso Health Group	BEARISH	$2.14B	-	-68.3%	-%	$2.5	Compare
ACHC Acadia Healthcare Company, Inc.	BEARISH	$2.17B	-	-41.0%	-33.3%	$23.52	Compare
NEOG Neogen Corporation	NEUTRAL	$2.09B	-	-25.6%	-69.9%	$9.61	Compare
PAHC Phibro Animal Health Corporation	NEUTRAL	$2.18B	23.84	31.8%	6.3%	$53.88	Compare

SNDX Syndax...

NEUTRAL

Mkt Cap

$2.1B

P/E

ROE

-161.8%

Price

$24.23

AHG Akso Health Group

Compare with SNDX

Compare with SNDX

NEOG Neogen Corporation

Compare with SNDX

PAHC Phibro Animal...

Compare with SNDX

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

Date	Insider	Position	Transaction	Shares	Value
2026-02-09	GOLDAN KEITH ALAN	Chief Financial Officer	Sale	3,410	$71,705
2026-02-09	METZGER MICHAEL A	Chief Executive Officer	Sale	17,159	$360,819
2026-02-06	GOLDAN KEITH ALAN	Chief Financial Officer	Sale	2,082	$42,931
2026-02-06	METZGER MICHAEL A	Chief Executive Officer	Sale	7,412	$152,835
2026-02-04	JARRETT A JENNIFER	Director	Stock Award	24,000	-
2026-02-04	RIZO ALEKSANDRA M.D. PH.D.	Director	Stock Award	24,000	-
2026-02-04	BOTWOOD NICHOLAS A.J.	Officer	Stock Award	60,000	-
2026-02-04	PODLESAK DENNIS G	Director	Stock Award	48,000	-
2026-02-04	KATKIN KEITH A	Director	Stock Award	24,000	-
2026-02-04	LEGAULT PIERRE	Director	Stock Award	24,000	-
2026-02-04	GOLDAN KEITH ALAN	Chief Financial Officer	Stock Award	52,250	-
2026-02-04	METZGER MICHAEL A	Chief Executive Officer	Stock Award	217,600	-
2026-02-04	HUBER MARTIN H JR	Director	Stock Award	24,000	-
2025-12-01	GOLDAN KEITH ALAN	Chief Financial Officer	Gift	1,224	-

GOLDAN KEITH ALAN

Chief Financial Officer

Sell

2026-02-09

3,410 shares · $71,705

METZGER MICHAEL A

Chief Executive Officer

Sell

2026-02-09

17,159 shares · $360,819

GOLDAN KEITH ALAN

Chief Financial Officer

Sell

2026-02-06

2,082 shares · $42,931

METZGER MICHAEL A

Chief Executive Officer

Sell

2026-02-06

7,412 shares · $152,835

JARRETT A JENNIFER

Director

Stock Award

2026-02-04

24,000 shares

RIZO ALEKSANDRA M.D. PH.D.

Director

Stock Award

2026-02-04

24,000 shares

BOTWOOD NICHOLAS A.J.

Officer

Stock Award

2026-02-04

60,000 shares

PODLESAK DENNIS G

Director

Stock Award

2026-02-04

48,000 shares

KATKIN KEITH A

Director

Stock Award

2026-02-04

24,000 shares

LEGAULT PIERRE

Director

Stock Award

2026-02-04

24,000 shares

GOLDAN KEITH ALAN

Chief Financial Officer

Stock Award

2026-02-04

52,250 shares

METZGER MICHAEL A

Chief Executive Officer

Stock Award

2026-02-04

217,600 shares

HUBER MARTIN H JR

Director

Stock Award

2026-02-04

24,000 shares

GOLDAN KEITH ALAN

Chief Financial Officer

Gift

2025-12-01

1,224 shares

Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

8-K

2026-02-26

10-K

2026-02-26

SNDX filed its annual 10-K report on February 26, 2026, which includes disclosures regarding its business operations, financial condition, and risk factors. Specific financial highlights and risk details were not provided in the available excerpts.

8-K

2026-01-12

8-K

2025-12-19

10-Q

2025-11-03

SNDX filed its quarterly 10-Q report on November 3, 2025. The filing includes a section on Risk Factors under Item 1A, although specific financial highlights and detailed risk disclosures were not provided in the available excerpts.

8-K

2025-11-03

SNDX filed an 8-K on November 3, 2025, likely to announce its third-quarter financial results.

8-K

2025-10-24

Denali Therapeutics Inc. (SNDX) filed a current report on October 24, 2025, likely announcing its third-quarter financial results.

10-Q

2025-08-04

SNDX filed its 10-Q on August 4, 2025. Due to the limited content provided in the excerpts, specific financial highlights and detailed risk factors are not available for summary.

8-K

2025-08-04

8-K

2025-06-26

8-K

2025-05-16

10-Q

2025-05-05

8-K

2025-05-05

DEF 14A

2025-04-01

10-K

2025-03-03

Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus

STRONG_BUY

11 analysts

Goldman Sachs

2026-04-01

Maintains

Buy Buy

Mizuho

2026-03-31

Maintains

Outperform Outperform

JP Morgan

2026-03-09

Maintains

Overweight Overweight

Citigroup

2026-03-02

Maintains

Buy Buy

BTIG

2025-12-09

reit

Buy Buy

Barclays

2025-11-24

Maintains

Overweight Overweight

JP Morgan

2025-11-12

Maintains

Overweight Overweight

UBS

2025-11-04

Maintains

Buy Buy

Barclays

2025-11-04

Maintains

Overweight Overweight

HC Wainwright & Co.

2025-10-27

reit

Buy Buy

Past News Coverage

Recent headlines mentioning SNDX from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V2 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends

SNDX

SNDX Syndax Pharmaceuticals, Inc. - Fundamental Analysis

At a glance

AI Analysis

Key Strengths

Key Risks

Performance Snowflake

Stock Price & Analyst Targets

Multi-Horizon Performance vs Peers

Historical Performance Trends

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Valuation Metrics

Profitability

Growth

Financial Health

Financial Statement Flow

Quarterly Earnings History

Healthcare Sector Comparison

Similar Companies

Recent Insider Trading

SEC Filings

Wall Street Analysts

Past News Coverage

Wait — Don't Miss Out!